Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Approved
Recipient : ARS Pharmaceuticals
Deal Size : $465.0 million
Deal Type : Licensing Agreement
ARS & ALK Partner to Commercialize neffy® in Europe, Canada, & More
Details : ALK exclusive rights to commercialize EURneffy (epinephrine nasal spray), the first and only needle-free emergency treatment for Type I allergic reactions including anaphylaxis.
Brand Name : EURneffy
Molecule Type : Small molecule
Upfront Cash : $145.0 million
November 11, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Approved
Recipient : ARS Pharmaceuticals
Deal Size : $465.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
